Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 30Cr
-0.34%+0.55%+3.37%+9.86% 5.07TCr
-2.22%-1.25%+391.53%+593.69% 3.97TCr
-0.54%+0.39%+27.67%-5.10% 3.47TCr
-1.36%+0.35%+19.34%+55.53% 3.32TCr
+1.21%-4.58%+3.00%+31.73% 2.68TCr
-1.81%-1.48% - - 1.68TCr
+0.51%-3.47%+66.38%+122.57% 1.54TCr
+0.44%+0.82%+15.13%+16.91% 1.38TCr
-0.62%-3.09%+11.43%-31.02% 1.28TCr
Average +0.09%-0.83%+67.23%+99.27% 2.71TCr
Weighted average by Cap. -0.65%-0.23%+82.71%+124.71%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-